BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33996154)

  • 1. Correlation between Prognostic Factors and the Histopathological Response to Neoadjuvant Chemotherapy in Osteosarcoma: A Retrospective Study.
    Prabowo Y; Setiawan I; Kamal AF; Kodrat E; Labib Zufar ML
    Int J Surg Oncol; 2021; 2021():8843325. PubMed ID: 33996154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma.
    Kim MS; Lee SY; Lee TR; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
    Ann Oncol; 2009 May; 20(5):955-60. PubMed ID: 19153123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.
    Kim SH; Shin KH; Moon SH; Kong Y; Suh JS; Yang WI
    J Surg Oncol; 2017 May; 115(6):752-759. PubMed ID: 28403564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.
    Bielack SS; Kempf-Bielack B; Delling G; Exner GU; Flege S; Helmke K; Kotz R; Salzer-Kuntschik M; Werner M; Winkelmann W; Zoubek A; Jürgens H; Winkler K
    J Clin Oncol; 2002 Feb; 20(3):776-90. PubMed ID: 11821461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
    Jeon DG; Song WS; Cho WH; Kong CB; Cho SH
    Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients.
    Nataraj V; Rastogi S; Khan SA; Sharma MC; Agarwala S; Vishnubhatla S; Bakhshi S
    Clin Transl Oncol; 2016 Sep; 18(9):937-44. PubMed ID: 26742936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
    Iwamoto Y; Tanaka K; Isu K; Kawai A; Tatezaki S; Ishii T; Kushida K; Beppu Y; Usui M; Tateishi A; Furuse K; Minamizaki T; Kawaguchi N; Yamawaki S
    J Orthop Sci; 2009 Jul; 14(4):397-404. PubMed ID: 19662473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma.
    Erdoğan F; Çinka H; Akman BÇ; Coşkun HS; Dabak N
    Jt Dis Relat Surg; 2023; 34(1):196-206. PubMed ID: 36700283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma.
    Jeon DG; Kong CB; Cho WH; Song WS; Cho SH; Choi SW; Lee SY
    J Surg Oncol; 2014 Mar; 109(3):275-9. PubMed ID: 24243222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
    Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
    BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?
    Xu J; Xie L; Guo W
    Clin Orthop Relat Res; 2018 Nov; 476(11):2177-2186. PubMed ID: 29912746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
    Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
    Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
    Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
    Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
    Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
    Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Osteosarcoma lung metastases. Survival after chemotherapy and surgery].
    Farfalli GL; Albergo JI; Lobos PA; Smith DE; Streitenberger PD; Pallotta Rodríguez MG; Aponte-Tinao LA
    Medicina (B Aires); 2015; 75(2):87-90. PubMed ID: 25919869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteosarcoma in Asian Populations Over the Age of 40 Years: A Multicenter Study.
    Joo MW; Shin SH; Kang YK; Kawai A; Kim HS; Asavamongkolkul A; Jeon DG; Kim JD; Niu X; Tsuchiya H; Puri A; Wang EH; Chung SH; Chung YG
    Ann Surg Oncol; 2015 Oct; 22(11):3557-64. PubMed ID: 25676843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
    Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
    Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
    Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
    J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma?
    Kushnir I; Kolander Y; Bickels J; Gortzak Y; Flusser G; Issakov J; Merimsky O
    Med Oncol; 2014 May; 31(5):936. PubMed ID: 24719037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.